Bruce L Wilkoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1871560/publications.pdf

Version: 2024-02-01

3034 7096 37,726 347 78 188 citations h-index g-index papers 349 349 349 22904 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
2	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
3	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
4	Dual-Chamber Pacing or Ventricular Backup Pacing in Patients With an Implantable Defibrillator. JAMA - Journal of the American Medical Association, 2002, 288, 3115.	7.4	1,799
5	Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 2685.	7.4	1,446
6	Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythm, 2009, 6, 1085-1104.	0.7	929
7	2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm, 2017, 14, e503-e551.	0.7	792
8	Quality of Life and Clinical Outcomes in Elderly Patients Treated with Ventricular Pacing as Compared with Dual-Chamber Pacing. New England Journal of Medicine, 1998, 338, 1097-1104.	27.0	584
9	ACR guidance document on MR safe practices: 2013. Journal of Magnetic Resonance Imaging, 2013, 37, 501-530.	3.4	582
10	Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients. Journal of the American College of Cardiology, 2008, 52, 541-550.	2.8	504
11	Lead Extraction in the Contemporary Setting: The LExICon Study. Journal of the American College of Cardiology, 2010, 55, 579-586.	2.8	503
12	Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope. JAMA - Journal of the American Medical Association, 2003, 289, 2224.	7.4	453
13	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. Journal of the American College of Cardiology, 2009, 53, 765-773.	2.8	424
14	Superior Vena Cava Defibrillator Coils Make Transvenous Lead Extraction More Challenging and Riskier. Journal of the American College of Cardiology, 2013, 61, 987-989.	2.8	421
15	Pacemaker lead extraction with the laser sheath: results of the pacing lead extraction with the excimer sheath (PLEXES) trial 11No financial support was received for performing the procedures or collecting the data, or for data analysis Journal of the American College of Cardiology, 1999, 33, 1671-1676.	2.8	416
16	2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm, 2017, 14, e97-e153.	0.7	308
17	Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm, 2010, 7, 353-360.	0.7	307
18	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 2012, 9, 1524-1576.	0.7	300

#	Article	IF	CITATIONS
19	Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm, 2016, 13, 2272-2278.	0.7	285
20	Clinical Study of the Laser Sheath for Lead Extraction: The Total Experience in the United States. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 804-808.	1.2	283
21	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. Heart Rhythm, 2008, 5, 907-925.	0.7	279
22	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	2.8	276
23	Five-Years Experience with Intravascular Lead Extraction. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2016-2020.	1.2	267
24	The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 121-135.	1.3	264
25	Recommendations for Extraction of Chronically Implanted Transvenous Pacing and Defibrillator Leads: Indications, Facilities, Training. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 544-551.	1.2	263
26	Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy Patients. Journal of Cardiovascular Electrophysiology, 2004, 15, 1002-1009.	1.7	260
27	Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. New England Journal of Medicine, 2019, 380, 1895-1905. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure:	27.0	251
28	implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	Article	IF	Citations
37	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.7	197
38	Clinical Benefits of Remote Versus Transtelephonic Monitoring of Implanted Pacemakers. Journal of the American College of Cardiology, 2009, 54, 2012-2019.	2.8	187
39	Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm, 2014, 11, 799-805.	0.7	183
40	Delayed Lead Perforation: A Disturbing Trend. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 251-253.	1.2	181
41	Tissue Synchronization Imaging and Optimal Left Ventricular Pacing Site in Cardiac Resynchronization Therapy. American Journal of Cardiology, 2006, 97, 1615-1621.	1.6	181
42	The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm, 2013, 10, e59-e65.	0.7	181
43	Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations. Circulation, 1996, 94, 1147-1166.	1.6	179
44	Noninvasive Electrocardiographic Mapping to Improve Patient Selection for Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2435-2443.	2.8	178
45	Critical Analysis of Dual-Chamber Implantable Cardioverter-Defibrillator Arrhythmia Detection. Circulation, 2001, 103, 381-386.	1.6	176
46	Exercise Testing for Chronotropic Assessment. Cardiology Clinics, 1992, 10, 705-717.	2.2	175
47	Complications arising after implantation of DDD pacemakers: the MOST experience. American Journal of Cardiology, 2003, 92, 740-741.	1.6	175
48	Analysis of Implantable Cardioverter Defibrillator Therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Journal of Cardiovascular Electrophysiology, 2003, 14, 940-948.	1.7	160
49	Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and GuidelinesEndorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE). Heart Rhythm, 2006, 3, 1250-1273.	0.7	160
50	(G) 17. Helite Miyaliii, 2000, 3, 1230-1273.		
50	Impact of Coronary Sinus Lead Position on Biventricular Pacing:. Journal of Cardiovascular Electrophysiology, 2004, 15, 1120-1125.	1.7	158
51	Impact of Coronary Sinus Lead Position on Biventricular Pacing:. Journal of Cardiovascular Electrophysiology, 2004, 15, 1120-1125. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace, 2014, 16, 1490-1495.	1.7	158 151
	Electrophysiology, 2004, 15, 1120-1125. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of		
51	Electrophysiology, 2004, 15, 1120-1125. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace, 2014, 16, 1490-1495. Biodegradation of polyether polyurethane inner insulation in bipolar pacemaker leads. Journal of	1.7	151

#	Article	IF	Citations
55	Safe Performance of Magnetic Resonance Imaging on Five Patients with Permanent Cardiac Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 913-919.	1.2	141
56	Outcomes of patients requiring emergent surgical or endovascular intervention for catastrophic complications during transvenous lead extraction. Heart Rhythm, 2014, 11, 419-425.	0.7	137
57	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	1.7	135
58	Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: The iTransmit study. Heart Rhythm, 2015, 12, 554-559.	0.7	125
59	The Role of Swab and Tissue Culture in the Diagnosis of Implantable Cardiac Device Infection. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1276-1281.	1.2	122
60	Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis, 2008, 59, 7-22.	1.4	122
61	Initial Experience With Larger Laser Sheaths for the Removal of Transvenous Pacemaker and Implantable Defibrillator Leads. Circulation, 1999, 100, 516-525.	1.6	121
62	Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm, 2010, 7, 466-471.	0.7	120
63	Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines. Heart Rhythm, 2009, 6, 869-885.	0.7	107
64	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2017, 135, 2310-2312.	1.6	107
65	Electrical dyssynchrony induced by biventricular pacing: Implications for patient selection and therapy improvement. Heart Rhythm, 2015, 12, 782-791.	0.7	100
66	Minimally Invasive Left Ventricular Epicardial Lead Placement: Surgical Techniques for Heart Failure Resynchronization Therapy. Annals of Thoracic Surgery, 2005, 79, 1536-1544.	1.3	97
67	The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. Current Opinion in Cardiology, 2001, 16, 66-71.	1.8	94
68	Usefulness of Atrioventricular Delay Optimization Using Doppler Assessment of Mitral Inflow in Patients Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2006, 98, 780-785.	1.6	93
69	Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration. Journal of the American College of Cardiology, 2012, 60, 592-598.	2.8	93
70	Outcome of Magnetic Resonance Imaging (MRI) in Selected Patients with Implantable Cardioverter Defibrillators (ICDs). PACE - Pacing and Clinical Electrophysiology, 2005, 28, 270-273.	1.2	92
71	Characterization of super-response to cardiac resynchronization therapy. Heart Rhythm, 2010, 7, 885-889.	0.7	91
72	The DAVID (Dual Chamber and VVI Implantable Defibrillator) II Trial. Journal of the American College of Cardiology, 2009, 53, 872-880.	2.8	89

#	Article	IF	CITATIONS
73	Remote monitoring of cardiovascular devices: a time and activity analysis. Heart Rhythm, 2012, 9, 1947-1951.	0.7	89
74	Intravascular Lead Extraction Using Locking Stylets, Sheaths, and Other Techniques. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1864-1870.	1.2	87
75	Safety of magnetic resonance imaging of patients with a new Medtronic EnRhythm MRI SureScan pacing system: clinical study design. Trials, 2008, 9, 68.	1.6	87
76	Catheter Ablation for Atrial Fibrillation inÂHeart Failure Patients. JACC: Clinical Electrophysiology, 2015, 1, 200-209.	3.2	86
77	Electrophysiologic characteristics and catheter ablation of ventricular tachyarrhythmias among patients with heart failure on ventricular assist device support. Heart Rhythm, 2012, 9, 859-864.	0.7	83
78	Catheter Ablation for Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2296-2304.	27.0	82
79	Remote Interrogation and Monitoring of Implantable Cardioverter Defibrillators. Journal of Interventional Cardiac Electrophysiology, 2004, 11, 161-166.	1.3	80
80	Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) Trial. Congestive Heart Failure, 2011, 17, 248-254.	2.0	79
81	Microbiology of Cardiac Implantable Electronic Device Infections. JACC: Clinical Electrophysiology, 2016, 2, 498-505.	3.2	79
82	Long-Term Reverse Remodeling With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2010, 55, 1788-1795.	2.8	78
83	Clinical Performance of the Implantable Cardioverter Defibrillator: Electrocardiographic Documentation of 101 Spontaneous Discharges. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 280-285.	1.2	71
84	Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: Analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm, 2010, 7, 1567-1571.	0.7	71
85	Intravascular pacemaker and defibrillator lead extraction: A state-of-the-art review. Heart Rhythm, 2004, 1, 739-745.	0.7	69
86	Initial experience with the Evolution mechanical dilator sheath for lead extraction: Safety and efficacy. Heart Rhythm, 2010, 7, 870-873.	0.7	67
87	The Epidemic of Inadequate Biventricular Pacing in Patients With Persistent or Permanent Atrial Fibrillation and Its Association With Mortality. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 370-376.	4.8	66
88	Strategies for the Safe Magnetic Resonance Imaging of Pacemaker-Dependent Patients. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1041-1046.	1.2	65
89	Optimal Combination of Discriminators for Differentiating Ventricular from Supraventricular Tachycardia by Dual-Chamber Defibrillators. Journal of Cardiovascular Electrophysiology, 2005, 16, 732-739.	1.7	65
90	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. Journal of the American College of Cardiology, 2009, 53, 600-607.	2.8	65

#	Article	IF	Citations
91	Role of CMR Imaging in Risk Stratification for Sudden Cardiac Death. JACC: Cardiovascular Imaging, 2013, 6, 392-406.	5.3	64
92	QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. American Journal of Cardiology, 2003, 92, 798-803.	1.6	63
93	Pacemaker and ICD leads: Strategies for long-term management. Journal of Interventional Cardiac Electrophysiology, 2008, 23, 59-72.	1.3	63
94	The QRS Narrowing Index Predicts Reverse Left Ventricular Remodeling Following Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 604-611.	1.2	62
95	Noninvasive Assessment of Cardiac Resynchronization Therapy for Congestive Heart Failure Using Myocardial Strain and Left Ventricular Peak Power as Parameters of Myocardial Synchrony and Function. Journal of Cardiovascular Electrophysiology, 2002, 13, 1203-1208.	1.7	61
96	Mortality of Heart Failure Patients After Cardiac Resynchronization Therapy: Identification of Predictors. Journal of Cardiovascular Electrophysiology, 2008, 19, 1259-1265.	1.7	60
97	Safety of Oral Dofetilide for Rhythm Control of Atrial Fibrillation and Atrial Flutter. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 772-776.	4.8	60
98	Low Incidence of Lead Related Complications Associated with Nonthoracotomy Implantable Cardioverter Defibrillator Systems. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 172-178.	1.2	59
99	Cardiac Resynchronization Therapy in Non-Left Bundle Branch Block Morphologies. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 590-595.	1.2	59
100	Transvenous extraction of implantable cardioverter-defibrillator leads under advisory—A comparison of Riata, Sprint Fidelis, and non-recalled implantable cardioverter-defibrillator leads. Heart Rhythm, 2013, 10, 1444-1450.	0.7	59
101	2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2020, 17, e220-e228.	0.7	55
102	The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm, 2012, 9, 24-31.	0.7	54
103	Cardiac Implantable Electronic DeviceÂlnfections. JACC: Clinical Electrophysiology, 2017, 3, 1-9.	3.2	54
104	Nonthoracotomy Implantable Defibrillator Lead Extraction:. Results and Comparison with Extraction of Pacemaker Leads. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1944-1950.	1.2	53
105	Worldwide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT). American Heart Journal, 2016, 180, 12-21.	2.7	53
106	Impact of Mitral Regurgitation on Reverse Remodeling and Outcome in Patients Undergoing Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2012, 5, 21-26.	2.6	52
107	Chronotropic Response to Exercise in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 179-187.	1.2	51
108	Azygos Vein Lead Implantation:. A Novel Adjunctive Technique for Implantable Cardioverter Defibrillator Placement. Journal of Cardiovascular Electrophysiology, 2004, 15, 780-783.	1.7	51

#	Article	IF	CITATIONS
109	Safe magnetic resonance imaging scanning of patients with cardiac rhythm devices: A role for computer modeling. Heart Rhythm, 2013, 10, 1815-1821.	0.7	51
110	Usefulness of Cardiac Resynchronization Therapy in Patients With Adriamycin-Induced Cardiomyopathy. American Journal of Cardiology, 2010, 105, 522-526.	1.6	50
111	Nomogram for predicting 30-day all-cause mortality after transvenous pacemaker and defibrillator lead extraction. Heart Rhythm, 2015, 12, 2381-2386.	0.7	50
112	How to treat and identify device infections. Heart Rhythm, 2007, 4, 1467-1470.	0.7	49
113	Effects of Extracorporeal Shock Wave Lithotripsy on Cardiac Pacemakers and its Safety in Patients with Implanted Cardiac Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1607-1616.	1.2	48
114	Considerations for cardiac device lead extraction. Nature Reviews Cardiology, 2016, 13, 221-229.	13.7	47
115	Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003108.	4.8	47
116	Predictors of Response to Cardiac Resynchronization Therapy in Patients With a Non-Left Bundle Branch Block Morphology. American Journal of Cardiology, 2011, 108, 1576-1580.	1.6	45
117	Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: Fate of "nonresponders― Heart Rhythm, 2014, 11, 412-416.	0.7	45
118	Multicenter experience with extraction of the Riata/Riata ST ICD lead. Heart Rhythm, 2014, 11, 1613-1618.	0.7	45
119	Percutaneous Treatment for Pacemaker-Associated Superior Vena Cava Syndrome. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1628-1633.	1.2	44
120	The Impact of Povidone-Iodine Pocket Irrigation Use on Pacemaker and Defibrillator Infections. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 789-794.	1.2	44
121	Improved Extraction of ePTFE and Medical Adhesive Modified Defibrillation Leads from the Coronary Sinus and Great Cardiac Vein. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 205-211.	1.2	44
122	Complications of Pacemakers and Defibrillators in the Elderly. The American Journal of Geriatric Cardiology, 2006, 15, 102-107.	0.6	44
123	The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. European Heart Journal, 2008, 29, 2497-2505.	2.2	44
124	Prognostic Value of Electrocardiographic Measurements Before and After Cardiac Resynchronization Device Implantation in Patients With Heart Failure due to Ischemic or Nonischemic Cardiomyopathy. American Journal of Cardiology, 2008, 101, 359-363.	1.6	43
125	QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Heart Rhythm, 2013, 10, 55-60.	0.7	43
126	The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: Rationale, Design, Results, Clinical Implications and Lessons for Future Trials. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 468-472.	1.0	42

#	Article	IF	CITATIONS
127	Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions. Heart Rhythm, 2017, 14, 1400-1404.	0.7	42
128	Transvenous Extraction of Pacemaker and Defibrillator Leads and the RiskÂofÂTricuspid Valve Regurgitation. JACC: Clinical Electrophysiology, 2018, 4, 1421-1428.	3.2	42
129	The World-wide Randomized Antibiotic Envelope Infection Prevention (WRAP-IT) trial: Long-term follow-up. Heart Rhythm, 2020, 17, 1115-1122.	0.7	42
130	Safe Scanning, but Frequent Artifacts Mimicking Bradycardia and Tachycardia During Magnetic Resonance Imaging (MRI) in Patients with an Implantable Loop Recorder (ILR). Annals of Noninvasive Electrocardiology, 2005, 10, 404-408.	1.1	41
131	Bridge to surgery: Best practice protocol derived from early clinical experience with the Bridge Occlusion Balloon. Federated Agreement from the Eleventh Annual Lead Management Symposium. Heart Rhythm, 2017, 14, 1574-1578.	0.7	41
132	Impact of Cardiac Implantable Electronic Device Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008280.	4.8	41
133	Successful Percutaneous Extraction of a Chronic Left Ventricular Pacing Lead. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1448-1451.	1.2	40
134	Evaluation of ventricular synchrony using novel Doppler echocardiographic indices in patients with heart failure receiving cardiac resynchronization therapy. Journal of the American Society of Echocardiography, 2004, 17, 845-850.	2.8	40
135	The Impact of Myocardial Viability on the Clinical Outcome of Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2009, 20, 50-57.	1.7	40
136	Interventional Electrophysiology and Cardiac Resynchronization Therapy. Circulation, 2007, 115, 2208-2220.	1.6	39
137	Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008503.	4.8	39
138	Safety and efficacy of radiofrequency energy catheter ablation of atrial fibrillation in patients with pacemakers and implantable cardiac defibrillators. Heart Rhythm, 2005, 2, 1309-1316.	0.7	38
139	Follow-up of Patients With New Cardiovascular Implantable Electronic Devices. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 108-116.	4.8	38
140	Cardiac Implantable Electronic Device Therapy in Heart Failure. Circulation Research, 2019, 124, 1584-1597.	4.5	37
141	Diagnosis of Sleep-Related Breathing Disorders by Visual Analysis of Transthoracic Impedance Signals in Pacemakers. Circulation, 2004, 110, 2562-2567.	1.6	36
142	Continuous Right Ventricular Volume Assessment by Catheter Measurement of Impedance for Antitachycardia System Control. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1918-1926.	1.2	35
143	Assessment of Pacemaker Chronotropic Response: Implementation of the Wilkoff Mathematical Model. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1748-1754.	1.2	34
144	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	1.2	34

#	Article	IF	CITATIONS
145	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.8	34
146	Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. American Journal of Cardiology, 2003, 91, 812-816.	1.6	31
147	Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007266.	4.8	31
148	Frequency and associations of symptomatic deterioration after dual-chamber defibrillator implantation in patients with ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2002, 90, 79-82.	1.6	30
149	Dynamic obstruction to coronary sinus access: The Thebesian valve. Heart Rhythm, 2006, 3, 1240-1241.	0.7	30
150	Pacing Lead Survival: Performance of Different Models. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1991-1995.	1.2	29
151	Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). Journal of Heart and Lung Transplantation, 2014, 33, 318-320.	0.6	29
152	Implantable Cardioverter-Defibrillators in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1119-1127.	4.5	29
153	Health values before and after pacemaker implantation. American Heart Journal, 2002, 144, 687-692.	2.7	28
154	Electrical Conduction Disturbance Effects on Dynamic Changes of Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2005, 46, 2270-2276.	2.8	28
155	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. Heart Rhythm, 2014, 11, 2156-2162.	0.7	28
156	The Impact of Changing Antiseptic Skin Preparation Agent used for Cardiac Implantable Electronic Device (CIED) Procedures on the Risk of Infection. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 240-246.	1.2	28
157	Lead failures: Dealing with even less perfect. Heart Rhythm, 2007, 4, 897-899.	0.7	27
158	Long-term Outcomes and Clinical Predictors for Pacing After Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 791-798.	0.6	27
159	QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm, 2012, 9, 1674-1678.	0.7	27
160	Competitive athletes with implantable cardioverter–defibrillators—How to program? Data from the Implantable Cardioverter–Defibrillator Sports Registry. Heart Rhythm, 2019, 16, 581-587.	0.7	27
161	Cardiac Venous Left Ventricular Lead Removal and Reimplantation Following Device Infection: A Large Singleâ€Center Experience. Journal of Cardiovascular Electrophysiology, 2012, 23, 1213-1216.	1.7	26
162	The biostability of cardiac lead insulation materials as assessed from longâ€ŧerm human implants. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2016, 104, 411-421.	3.4	26

#	Article	IF	CITATIONS
163	Transvenous lead extraction at the time of cardiac implantable electronic device upgrade: Complexity, safety, and outcomes. Heart Rhythm, 2017, 14, 1807-1811.	0.7	26
164	The Use of Beep-O-Grams in the Assessment of Automatic Implantahle Cardioverter Defibrillator Sensing Function. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1737-1745.	1.2	25
165	Cardiac lead extraction with a novel locking stylet. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 591-593.	1.3	25
166	Management of cardiac implantable electronic device infections: the challenges of understanding the scope of the problem and its associated mortality. Expert Review of Cardiovascular Therapy, 2013, 11, 607-616.	1.5	25
167	Six-Year Clinical Experience with the Automatic Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1850-1854.	1.2	24
168	The impact of left ventricular size on response to cardiac resynchronization therapy. American Heart Journal, 2011, 162, 646-653.	2.7	24
169	North American Society of Pacing and Electrophysiology. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 127-131.	1.2	23
170	Pacemaker and ICD Malfunction—An Incomplete Picture. JAMA - Journal of the American Medical Association, 2006, 295, 1944.	7.4	23
171	Effect of Pacing for Soft Indications on Mortality and Heart Failure in the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 828-837.	1.2	23
172	Effectiveness of implantable cardioverter-defibrillator lead coil treatments in facilitating ease of extraction. Heart Rhythm, 2010, 7, 890-897.	0.7	23
173	Survival After Rate-Responsive Programming in Patients With Cardiac Resynchronization Therapy-Defibrillator Implants Is Associated With a Novel Parameter. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	23
174	Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 396-401.	1.2	23
175	Optimal Small-Capacitor Biphasic Waveform for External Defibrillation. Circulation, 1998, 98, 2487-2493.	1.6	22
176	Extraction of Implantable Cardiac Electronic Devices. Current Cardiology Reports, 2011, 13, 407-414.	2.9	22
177	Correlation of Impedance Minute Ventilation with Measured Minute Ventilation in a Rate Responsive Pacemaker. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 989-993.	1.2	21
178	Survival of Patients With Biventricular Devices After Device Infection, Extraction, and Reimplantation. JACC: Heart Failure, 2013, 1, 508-513.	4.1	21
179	Short- and long-term electrical performance of the 5086MRI pacing lead. Heart Rhythm, 2014, 11, 222-229.	0.7	21
180	Incidence, indications, risk factors, and survival of patients undergoing cardiac implantable electronic device implantation after open heart surgery. Europace, 2017, 19, euw234.	1.7	21

#	Article	IF	CITATIONS
181	Incidence and predictors of late atrioventricular conduction recovery among patients requiring permanent pacemaker for complete heart block after cardiac surgery. Heart Rhythm, 2017, 14, 1786-1792.	0.7	21
182	The Effects of Percutaneous Catheter Ablation on Preexisting Permanent Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 1637-1645.	1.2	20
183	Design of the P acemaker RE mote F ollow-up E valuation and R eview (PREFER) trial to assess the clinical value of the remote pacemaker interrogation in the management of pacemaker patients. Trials, 2008, 9, 18.	1.6	20
184	Transiliac ICD implantation: Defibrillation vector flexibility produces consistent success. Heart Rhythm, 2009, 6, 978-983.	0.7	20
185	A Heart Rhythm Society Electrophysiology Workforce Study: Current survey analysis of physician workforce trends. Heart Rhythm, 2010, 7, 1346-1355.	0.7	20
186	Elevated Red Cell Distribution Width Is Associated With Impaired Reverse Ventricular Remodeling and Increased Mortality in Patients Undergoing Cardiac Resynchronization Therapy. Congestive Heart Failure, 2012, 18, 79-84.	2.0	20
187	Noninvasive Mapping of Electrical Dyssynchrony in Heart Failure and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 125-134.	1.7	20
188	Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm, 2015, 12, 517-523.	0.7	20
189	Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. Europace, 2018, 20, 1621-1629.	1.7	20
190	Risk Factors for CIED Infection After Secondary Procedures. JACC: Clinical Electrophysiology, 2022, 8, 101-111.	3.2	20
191	Adequacy of implantable cardioverter-defibrillator lead placement for tachyarrhythmia detection by sinus rhythm electrogram amplitude. American Journal of Cardiology, 1995, 76, 1162-1166.	1.6	19
192	Experience with a Dual Chamber Implantable Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1041-1048.	1.2	19
193	Matching Approved "Nondedicated" Hardware to Obtain Biventricular Pacing and Defibrillation: Feasibility and Troubleshooting. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1066-1071.	1.2	19
194	Standardized MR Terminology and Reporting of Implants and Devices as Recommended by the American College of Radiology Subcommittee on MR Safety. Radiology, 2015, 274, 866-870.	7.3	19
195	Echocardiographic Predictors of Longâ€Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric?. Journal of Cardiovascular Electrophysiology, 2017, 28, 410-415.	1.7	19
196	Infectious consequences of hematoma from cardiac implantable electronic device procedures and the role of the antibiotic envelope: A WRAP-IT trial analysis. Heart Rhythm, 2021, 18, 2080-2086.	0.7	19
197	Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England. Value in Health, 2021, 24, 930-938.	0.3	19
198	Large Change in Voltage at Phase Reversal Improves Biphasic Defibrillation Thresholds. Circulation, 1996, 94, 1768-1773.	1.6	19

#	Article	IF	CITATIONS
199	Transiliac permanent pacemaker implantation after extraction of infected pectoral pacemaker systems. American Journal of Cardiology, 1999, 84, 474-475.	1.6	18
200	Device Features for Managing Patients with Heart Failure. Heart Failure Clinics, 2011, 7, 215-225.	2.1	18
201	Follow-up of patients with new cardiovascular implantable electronic devices: Is adherence to the experts' recommendations associated with improved outcomes?. Heart Rhythm, 2013, 10, 1127-1133.	0.7	18
202	Pacemaker implantation in pediatric heart transplant recipients: Predictors, outcomes, and impact on survival. Heart Rhythm, 2015, 12, 1776-1781.	0.7	18
203	Lead Location as Assessed on CardiacÂComputed Tomography andÂDifficulty ofÂPercutaneous Transvenous Extraction. JACC: Clinical Electrophysiology, 2019, 5, 1432-1438.	3.2	18
204	Use of virtual visits for the care of the arrhythmia patient. Heart Rhythm, 2020, 17, 1779-1783.	0.7	18
205	Safe, sensible, sagacious: responsible scanning of pacemaker patients. European Heart Journal, 2005, 26, 1683-1684.	2.2	17
206	QRS Fragmentation Is Not Associated with Poor Response to Cardiac Resynchronization Therapy. Annals of Noninvasive Electrocardiology, 2011, 16, 165-171.	1.1	17
207	Effect of PR interval prolongation on long-term outcomes in patients with left bundle branch block vs non–left bundle branch block morphologies undergoing cardiac resynchronization therapy. Heart Rhythm, 2017, 14, 1523-1528.	0.7	17
208	Transvenous Lead Extraction in Chronic Kidney Disease and Dialysis Patients With Infected Cardiac Devices. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005706.	4.8	17
209	Effect of Cardiac Resynchronization Therapy on Left Ventricular Remodeling in Patients With Cardiac Sarcoidosis. American Journal of Cardiology, 2019, 123, 329-333.	1.6	17
210	Early Clinical Experience with a Minute Ventilation Sensor DDDR Pacemaker. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1815-1820.	1.2	16
211	Influence of Posture, Breathing Pattern, and Type of Exercise on Minute Ventilation Estimation by a Pacemaker Transthoracic Impedance Sensor. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1767-1771.	1.2	16
212	Insights From Internetâ€Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program. Congestive Heart Failure, 2010, 16, 159-163.	2.0	16
213	Prognostic Significance of Atrial Arrhythmias in a Primary Prevention ICD Population. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1070-1079.	1.2	16
214	Chest radiography is a poor predictor of left ventricular lead position in patients undergoing cardiac resynchronization therapy: comparison with multidetector computed tomography. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 59-65.	1.3	16
215	Safety of repetitive nerve stimulation in patients with cardiac implantable electronic devices. Muscle and Nerve, 2013, 47, 840-844.	2.2	16
216	Incidence, management, and outcomes of the arteriovenous fistula complicating transvenous lead extraction. Heart Rhythm, 2014, 11, 404-411.	0.7	16

#	Article	IF	Citations
217	A Device Histogramâ€Based Simple Predictor of Mortality Risk in ICD and CRTâ€D Patients: The Heart Rate Score. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 333-343.	1.2	16
218	Magnetic Resonance Imaging Conditional Pacemakers: Rationale, Development and Future Directions. Indian Pacing and Electrophysiology Journal, 2012, 12, 204-212.	0.6	15
219	MRI in patients with cardiac implantable electronic devices. Expert Review of Medical Devices, 2012, 9, 139-146.	2.8	15
220	Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks. Heart Rhythm, 2015, 12, 1370-1375.	0.7	15
221	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2015, 115, 82-85.	1.6	15
222	Unrecognized venous injuries after cardiac implantable electronic device transvenous lead extraction. Heart Rhythm, 2018, 15, 318-325.	0.7	15
223	Sawtooth First Phase Biphasic Defibrillation Waveform Journal of Cardiovascular Electrophysiology, 1997, 8, 517-528.	1.7	14
224	ICDs: Dealing with Less Than Perfect. Journal of Cardiovascular Electrophysiology, 2005, 16, 796-797.	1.7	14
225	Giant Flow Reversal in Pulmonary Venous Flow as a Possible Mechanism for Asynchronous Pacing-induced Heart Failure. Journal of the American Society of Echocardiography, 2005, 18, 722-728.	2.8	14
226	Fibrotic Tissue Growth into the Extendable Lobes of an Active Fixation Coronary Sinus Lead Can Complicate Extraction. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e64-5.	1.2	14
227	Cost efficiency and reimbursement of remote monitoring: a US perspective. Europace, 2013, 15, i54-i58.	1.7	14
228	Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRXâ,,¢ antibacterial envelope. Europace, 2021, 23, iv33-iv44.	1.7	14
229	Shorter AV Delays Provide Improved Echocardiographic Hemodynamics during Exercise in Patients Receiving Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 457-465.	1.2	13
230	Survival in Octogenarians Undergoing Cardiac Resynchronization Therapy Compared to the General Population. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 740-744.	1.2	13
231	Extracción de electrodos transvenosos de dispositivos electrónicos implantables cardiacos: ¿quién, cuándo, cómo y dónde?. Revista Espanola De Cardiologia, 2016, 69, 3-6.	1.2	13
232	I Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantablecardioverter defibrillators to reduce patient morbidity [NCT00279279]. Trials, 2006, 7, 18.	1.6	12
233	Cardiac Implantable Electronic Device Infections: Facts, Current Practice, and the Unanswered Questions. Current Infectious Disease Reports, 2014, 16, 425.	3.0	12
234	Safety of Oral Dofetilide Reloading for Treatment of Atrial Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	12

#	Article	IF	CITATIONS
235	Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 329-334.	1.0	12
236	DDIR Versus VVIR Pacing in Patients with Paroxysmal Atrial Tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1630-1638.	1.2	11
237	Long-Term Performance of Epimyocardial Pacing Leads in Adults: Comparison with Endocardial Leads. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 412-417.	1.2	11
238	Optimized First Phase Tilt in "Parallel-Series" Biphasic Waveform. Journal of Cardiovascular Electrophysiology, 1997, 8, 649-657.	1.7	11
239	Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial., 2001, 2, 215.		11
240	Rate Responsive Pacing Using Transthoracic Impedance Minute Ventilation Sensors: A Multicenter Study on Calibration Stability. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1679-1684.	1.2	11
241	A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 12.	1.5	11
242	Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity. Heart Rhythm, 2012, 9, 1619-1626.	0.7	11
243	Percutaneous extraction of stented device leads. Heart Rhythm, 2012, 9, 723-727.	0.7	11
244	Clinical Presentation, Timing, and Microbiology of CIED Infections. JACC: Clinical Electrophysiology, 2021, 7, 50-61.	3.2	11
245	Combined Minimally Invasive Pulmonary Vein Isolation, Left Atrial Appendage Excision and Cardiac Resynchronization Therapy for Heart Failure: Case Report. Heart Surgery Forum, 2005, 8, E249-E252.	0.5	11
246	The Benefits of Biventricular Pacing in Heart Failure Patients with Narrow QRS, NYHA Class II and Right Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 193-198.	1.2	10
247	Successful stent implantation for superior vena cava injury during transvenous lead extraction. HeartRhythm Case Reports, 2015, 1, 394-396.	0.4	10
248	Strain-time curve analysis by speckle tracking echocardiography in cardiac resynchronization therapy: Insight into the pathophysiology of responders vs. non-responders. Cardiovascular Ultrasound, 2015, 14, 14.	1.6	10
249	Left Ventricular Size does not Modify the Effect of QRS Duration in Predicting Response to Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 482-487.	1.2	10
250	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008991.	4.8	10
251	Cardiac venous injuries: Procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm, 2020, 17, 1298-1303.	0.7	10
252	Additional Lead Improves Defibrillation Efficacy With an Abdominal †Hot Can' Electrode System. Circulation, 1997, 96, 4400-4407.	1.6	10

#	Article	IF	Citations
253	Bradyarrhythmias. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 291-298.	0.9	9
254	Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity. Nature Reviews Cardiology, 2010, 7, 376-383.	13.7	9
255	Conductor externalization of the Biotronik Kentrox internal cardioverter-defibrillator lead: The tip of another iceberg?. Heart Rhythm, 2014, 11, 1648-1650.	0.7	9
256	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 2972-2982.	3.1	9
257	Effects of Polarity on Defibrillation Thresholds Using a Biphasic Waveform in a Hot Can Electrode System. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2911-2916.	1.2	8
258	Leadâ€Induced Venous Thrombosis:. Journal of Cardiovascular Electrophysiology, 2004, 15, 1263-1264.	1.7	8
259	Baseline Right Ventricular Dysfunction Predicts Worse Outcomes in Patients Undergoing Cardiac Resynchronization Therapy Implantation. Journal of Cardiac Failure, 2020, 26, 227-232.	1.7	8
260	The gap between what patients know and desire to learn about their cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 118-122.	1.2	8
261	Heart rate score, a measure related to chronotropic incompetence in pacemaker patients. Heart Rhythm O2, 2021, 2, 124-131.	1.7	8
262	Use of an Intracardiac Electrogram Eliminates the Need for a Surface ECG during Implantable Cardioverterâ€Defibrillator Followâ€Up. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1432-1437.	1.2	7
263	Clinical Experience and Procedural Outcomes Associated with the DF4 Implantable Cardioverter Defibrillator System: The SJ4 Postapproval Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 855-862.	1.2	7
264	Long-Term Outcomes in Patients With a Left Ejection FractionÂâ‰\$5% Undergoing CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 36-46.	3.2	7
265	A Comparison of the AVID and DAVID Trials of Implantable Defibrillators. American Journal of Cardiology, 2005, 95, 1431-1435.	1.6	6
266	Design and Rationale of the Assessment of Proper Physiologic Response with Rate Adaptive Pacing Driven by Minute Ventilation or Accelerometer (APPROPRIATE) Trial. Journal of Cardiovascular Translational Research, 2011, 4, 21-26.	2.4	6
267	Coronary Sinus Lead Extraction. Cardiac Electrophysiology Clinics, 2015, 7, 661-671.	1.7	6
268	RemovalÂof subcutaneous defibrillator shocking coils: Lessons to learn for future extraction of subcutaneous defibrillator systems. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1341-1344.	1.2	6
269	Addition of minute ventilation to rate-response pacing improves heart rate score more than accelerometer alone. Heart Rhythm, 2018, 15, 1730-1735.	0.7	6
270	Predictors of longâ€ŧerm outcomes greater than 10 years after cardiac resynchronization therapy implantation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1182-1186.	1.7	6

#	Article	IF	Citations
271	Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 62-72.	3.2	6
272	Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations. Europace, 2021, 23, iv28-iv32.	1.7	6
273	InÂvitro modeling accurately predicts cardiac lead fracture at 10 years. Heart Rhythm, 2021, 18, 1605-1612.	0.7	6
274	Infections associated with cardiac implantable electronic devices are misunderstood. Texas Heart Institute Journal, 2011, 38, 353-4.	0.3	6
275	Novel ventricular tachyarrhythmia detection enhancement detects undertreated life-threatening arrhythmias. Heart Rhythm O2, 2022, 3, 70-78.	1.7	6
276	Heart rate, pacing, and outcome in the Dual Chamber and VVI Implantable Defibrillator (DAVID) trials. Heart Rhythm, 2009, 6, 1129-1135.	0.7	5
277	A Clinical Prediction Rule to Identify Patients at Heightened Risk for Early Demise Following Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 278-282.	1.7	5
278	Coronary Sinus Lead Extraction. Heart Failure Clinics, 2017, 13, 105-115.	2.1	5
279	Transvenous Lead Extraction: A Clinical Commentary for Anesthesiologists. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1101-1111.	1.3	5
280	Rapid ventricular pacing during transcatheter valve procedures using an internal device and programmer: A demonstration of feasibility. Catheterization and Cardiovascular Interventions, 2020, 95, 1042-1048.	1.7	5
281	Criteria for Optimal Pacemaker Function. Journal of Cardiovascular Electrophysiology, 1991, 2, 416-418.	1.7	4
282	ICDs: Evidence, guidelines and glitches. Heart Rhythm, 2011, 8, 800-803.	0.7	4
283	Guidance for the Heart Rhythm Society Pertaining to Interactions with Industry. Heart Rhythm, 2011, 8, e19-e25.	0.7	4
284	Improved Programming of ICDs. New England Journal of Medicine, 2012, 367, 2348-2349.	27.0	4
285	Shock Avoidance and the Newer Tachycardia Therapy Algorithms. Cardiology Clinics, 2014, 32, 191-200.	2.2	4
286	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. American Journal of Cardiology, 2015, 115, 918-923.	1.6	4
287	Advances in cardiac implantable electronic device infection prevention: should we push the envelope?. Future Cardiology, 2018, 14, 359-366.	1.2	4
288	Proarrhythmic effects from competitive atrial pacing and potential programming solutions. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 720-729.	1.2	4

#	Article	IF	Citations
289	Lower rate limit for pacing by cardiac resynchronization defibrillators: Should lower rate programming be reconsidered?. Heart Rhythm, 2021, 18, 2087-2093.	0.7	4
290	Transvenous Lead Extraction of Cardiac Implantable Electronic Devices: Who, When, How and Where?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 3-6.	0.6	3
291	Cautery selection for oculofacial plastic surgery in patients with implantable electronic devices. European Journal of Ophthalmology, 2019, 29, 315-322.	1.3	3
292	Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008168.	4.8	3
293	Exercise Ventricular Rates, Cardiopulmonary Exercise Performance, and Mortality in Patients With Heart Failure With Atrial Fibrillation. Circulation: Heart Failure, 2021, 14, e007451.	3.9	3
294	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009344.	4.8	3
295	Predictors of Cardiac Implantable Electronic Device Artifact on Cardiac MRI: The Utility of a Device Related Score. Heart Lung and Circulation, 2021, 30, 1348-1355.	0.4	3
296	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	2.9	3
297	Implantable Cardioverter-Defibrillator: Technical Aspects. , 2004, , 970-979.		3
298	Influence of "high―defibrillation thresholds on patient survival and impact of system modification. Journal of Cardiovascular Electrophysiology, 2022, 33, 234-240.	1.7	3
299	Risk factors for hematoma in patients undergoing cardiac device procedures: A WRAP-IT trial analysis. Heart Rhythm O2, 2022, 3, 466-473.	1.7	3
300	Effect of Implantable Defibrillator Patch Electrodes on Left Ventricular Filling. Journal of Interventional Cardiology, 1989, 2, 161-166.	1.2	2
301	Effects of Respiration Phase on Ventricular Defibrillation Threshold in a Hot Can Electrode System. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1216-1224.	1.2	2
302	Biventricular Shocking Leads Improve Defibrillation Efficacy. Journal of Cardiovascular Electrophysiology, 1999, 10, 561-565.	1.7	2
303	Voltage Dependence of ICD Lead Polarization and the Effect of Iridium Oxide Coating. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 818-823.	1.2	2
304	The Strength-Duration Relationship of Monophasic Waveforms with Varying Capacitance Sizes in External Defibrillation. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2213-2218.	1.2	2
305	Current Concepts in Intravascular Pacemaker and Defibrillator Lead Extraction. , 0, , 124-133.		2
306	Remote Cardiac Monitoring in Patients With Heart Failure. Congestive Heart Failure, 2008, 14, 4-6.	2.0	2

#	Article	IF	CITATIONS
307	How to diagnose and manage patients with cardiac implantable electronic device infections. Journal of Arrhythmia, 2013, 29, 320-324.	1.2	2
308	Comparative Efficacy of Cardiac Resynchronization Therapy in Africans Americans Compared With European Americans. American Journal of Cardiology, 2015, 116, 1101-1105.	1.6	2
309	Advances in implantable cardioverter defibrillator therapy. Expert Review of Cardiovascular Therapy, 2016, 14, 291-299.	1.5	2
310	Lead Extraction Considerations for the Referring Cardiologist. Cardiology in Review, 2017, 25, 17-21.	1.4	2
311	Lead Removal and Extraction. , 2017, , 937-958.		2
312	Long term outcomes in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 1979-1983.	1.7	2
313	Transvenous lead extraction in patients with prior extraction procedures: Procedural profiles and outcomes. Heart Rhythm, 2020, 17, 1904-1908.	0.7	2
314	Superior vena cava reconstruction and implantation of a leadless pacemaker for management of pacemaker-induced superior vena cava syndrome. HeartRhythm Case Reports, 2019, 5, 539-541.	0.4	2
315	Description and Evaluation of the Res-QTMArrhythmia Control Device. Journal of Cardiovascular Electrophysiology, 1995, 6, 147-161.	1.7	1
316	Current status and future expectations for multisite pacing in heart failure. Current Cardiology Reports, 2002, 4, 238-247.	2.9	1
317	ICD Lead Extraction: When, Why and How?., 0,, 327-334.		1
318	Advances in Remote Monitoring of Implantable Cardiac Devices. Cardiac Electrophysiology Clinics, 2011, 3, 463-472.	1.7	1
319	Staphylococcus aureus Bacteremia and Endocarditis. Infectious Diseases in Clinical Practice, 2011, 19, 376-381.	0.3	1
320	Understanding lead dysfunction: Managing lead failure grief. Heart Rhythm, 2013, 10, 1460-1461.	0.7	1
321	Implantable Cardioverter Defibrillators. , 2014, , 1139-1150.		1
322	Interruption of Pacing Following Nonsustained Ventricular Tachycardia in an AAI Programmed Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1082-1090.	1.2	1
323	Nomenclature, Definitions, and Metrics of Cardiovascular Implantable Electronic Device Lead Management. Cardiac Electrophysiology Clinics, 2018, 10, 609-613.	1.7	1
324	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	3.9	1

#	Article	IF	CITATIONS
325	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. Journal of Medical Economics, 2020, 23, 1401-1408.	2.1	1
326	Biodegradation of polyether polyurethane inner insulation in bipolar pacemaker leads. Journal of Biomedical Materials Research Part B, 2001, 58, 302-307.	3.1	1
327	Clinical Experience with the Combination of an Antitachycardia Pacemaker (Orthocor II) and the Implantable Cardioverter-Defibrillator in Drug-Refractory Ventricular Tachycardia. Journal of Interventional Cardiology, 1990, 3, 269-276.	1.2	О
328	Group Purchasing Organizations: Optimizing Cardiac Device Selection, Therapy Delivery, and Fiscal Responsibility. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 1404-1409.	1.2	0
329	Prevention and Management of Procedural Complications. , 2011, , 741-746.		0
330	CRT or CRT-D devices? The case for â€~high energy' devices. Heart Failure Reviews, 2012, 17, 777-779.	3.9	0
331	Every life counts. Heart Rhythm, 2012, 9, 1239-1240.	0.7	0
332	Letter to Editor Response: Percutaneous extraction of stented device leads. Heart Rhythm, 2012, 9, e16.	0.7	0
333	Collaboration and engagement drive Heart Rhythm Society progress. Heart Rhythm, 2012, 9, 630-631.	0.7	0
334	Cardiac resynchronization therapy for exerciseâ€induced left ventricular dysfunction in the setting of left bundle branch block: A case report and review of the literature. Journal of Arrhythmia, 2014, 30, 519-521.	1.2	0
335	Bridging the gap between heart failure and the device clinic. Expert Review of Medical Devices, 2017, 14, 601-607.	2.8	0
336	Establishing and Managing a Device Clinic and Database. , 2017, , 1191-1200.		0
337	Implantable Cardioverter Defibrillators. , 2018, , 1101-1112.		0
338	Lead Management for Electrophysiologists. Cardiac Electrophysiology Clinics, 2018, 10, xiii-xiv.	1.7	0
339	Overview of Lead Management. Cardiac Electrophysiology Clinics, 2018, 10, 549-559.	1.7	O
340	Conversion, Compromise, and Conversation—Moving to a Sensible Middle When Addressing Implantable Cardioverter-Defibrillator Therapy. JAMA Cardiology, 2019, 4, 1049.	6.1	0
341	Hypothermia Outcomes After Transvenous Lead Extraction Complications Requiring Cardiothoracic Surgery. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007831.	4.8	0
342	Heart rate score predicts mortality independent of shocks in ICD and CRT-D patients. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 103-111.	1.3	0

#	ARTICLE	IF	CITATIONS
343	Techniques and Devices for Lead Extraction. , 2011, , 747-770.		0
344	Device Therapy in Heart Failure., 2011,, 694-703.		0
345	The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations., 2013,, 611-620.		O
346	Abstract 23072: Unrecognized Venous Injuries After Cardiac Implantable Electronic Device Transvenous Lead Extraction. Circulation, 2017, 136, .	1.6	0
347	Innovative Approaches and Technology Platforms for Pacemaker Lead Extraction., 2022,, 417-430.		0